Researchers based at the City University of New York (CUNY) have designed a deep learning artificial intelligence (AI) model that can improve preclinical predictions of drug responses in humans. As outlined in the Oct. 17, 2022, online issue of Nature Machine Intelligence, the researchers believe their model – a context-aware deconfounding autoencoder (CODE-AE) – can help improve the quality of early drug response prediction and help reduce subsequent clinical trial failures.
At the recent European Association of Nuclear Medicine meeting in Barcelona, researchers from the British Columbia Cancer Research Institute and the University of British Columbia reported the development and preclinical evaluation of bispecific radiotracers designed to target prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP).
China's National Medical Products Administration (NMPA) has cleared an IND application for a clinical trial of Shanghai Henlius Biotech Inc.'s HLX-60 for the treatment of solid tumors and lymphomas.
Hpvac SA has announced new data on its lead compound Hpvac-13 for the treatment and prevention of asthmatic attacks in an animal disease model of allergic asthma.
Zymeworks Inc. has described new antibody-drug conjugates (ADCs) consisting of a cysteine engineered full-length antibody (IgG type) targeting hepatocyte growth factor receptor (HGFR; MET) or folate receptor α (FOLR1; FR- α) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Suzhou Zelgen Biosciences Co. Ltd. has identified new compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Keythera (Suzhou) Pharmaceuticals Co. Ltd. has divulged new tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of alopecia areata, rheumatoid arthritis, lupus erythematosus, inflammation, allergy, cancer, metabolic diseases and transplant rejection, among other disorders.
Medshine Discovery Inc. has disclosed new benzylaminoquinazoline derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Impact Therapeutics Inc. has described five-membered heteroaryl-pyrimidine compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Nkgen Biotech Inc. has received IND clearance from the FDA for a phase I study of its cryopreserved off-the-shelf allogeneic blood-derived natural killer (NK) cell therapy SNK-02, to evaluate safety and tolerability in participants with pathologically confirmed solid tumors refractory to standard-of-care therapy.
RSS
